Particle size-dependent triggering of accelerated blood clearance phenomenon.
about
Sizing nanomaterials in bio-fluids by cFRAP enables protein aggregation measurements and diagnosis of bio-barrier permeability.Interactions of nanomaterials and biological systems: Implications to personalized nanomedicineImpact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricaseAn optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasisAccelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs.Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles.PEGylation as a strategy for improving nanoparticle-based drug and gene deliveryUnderstanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.Targeted polymeric therapeutic nanoparticles: design, development and clinical translationAccelerated Blood Clearance Phenomenon Reduces the Passive Targeting of PEGylated Nanoparticles in Peripheral Arterial Disease.Ascorbyl palmitate/d-α-tocopheryl polyethylene glycol 1000 succinate monoester mixed micelles for prolonged circulation and targeted delivery of compound K for antilung cancer therapy in vitro and in vivo.Polymeric micelles as a new drug carrier system and their required considerations for clinical trials.The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy.New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment.Hyaluronic acid-modified didecyldimethylammonium bromide/ d-a-tocopheryl polyethylene glycol succinate mixed micelles for delivery of baohuoside I against non-small cell lung cancer: in vitro and in vivo evaluation.Suppressive immune response of poly-(sarcosine) chains in peptide-nanosheets in contrast to polymeric micelles.Effects of poly(ethylene glycol) grafting density on the tumor targeting efficacy of nanoparticles with ligand modification.MPEG-hexPLA micelles as novel carriers for hypericin, a fluorescent marker for use in cancer diagnostics.Precisely tunable engineering of sub-30 nm monodisperse oligonucleotide nanoparticlesFactors influencing in vivo disposition of polymeric micelles on multiple administrations.Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug.A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid.In Vitro Evaluation of Anti-Aggregation and Degradation Behavior of PEGylated Polymeric Nanogels under In Vivo Like Conditions.Measuring absolute nanoparticle number concentrations from particle count time series.Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.
P2860
Q27324846-88A8ED7D-0CD1-4A40-9003-ACEEF11D34F0Q28391849-93641B8B-2DEA-47F2-BE0C-EF79802A5F42Q28727969-E9A4B446-F0EE-4DBF-9862-1058AE20165BQ34565059-18772AE8-20FF-4DFC-8135-2A6308CBE453Q35624235-162DB2C9-477C-4726-8B40-A65C6BDC75E9Q36058748-B9221B31-2454-4A78-A932-7EA2BBDD6FDBQ36703361-601ACCE2-2ADE-45BA-B43F-BD28BA7FAEE3Q36739647-BE59BDD9-68C3-49E6-9C0C-24CB81AFC972Q36934007-22E9C0F3-92A7-4041-A9D6-E243B5EBEFC4Q37123107-EE2FDB92-9B5D-450B-B42D-E030BDCEF06CQ37596129-85B5ABFA-7455-4FF2-B207-C81923958809Q37679942-191CA740-4A06-443F-9399-3CC4D191DCBCQ37815479-5E2AF3D5-9AC9-4B29-B4CD-107C2BCD72E4Q38135276-3C128B97-7178-483B-ACA0-CF8BD5537235Q38537004-80322991-4CF1-47E3-A024-2A99DA2FA965Q38718182-6C6C2124-9D6B-4086-B74A-5BD850C27C88Q38991300-6566C121-A5DD-4B7A-AF85-B926825B4A2EQ39064707-605A9905-381D-476E-9A96-29C7AB501B4BQ39804367-9FA3CC01-F5DC-4736-AEE6-6E8353EA4269Q41790614-060C85BD-15ED-4953-9A17-E693FEC54D35Q41992869-E242FD64-62F3-471D-ABF0-92D9DCA108B2Q43993972-1B8A0F89-AF65-43CF-9AFD-106C2CE8FD8FQ47162722-65C3C584-BE02-47EB-AFC1-497A62245AD4Q47334555-C2AAD1F1-D4DA-441D-9D72-E0BFDD63A286Q48727750-72082703-D283-4EBB-9300-49E292C0AAB3Q54118354-C979F502-857F-4EDF-877C-8C6EB5F13D13
P2860
Particle size-dependent triggering of accelerated blood clearance phenomenon.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Particle size-dependent triggering of accelerated blood clearance phenomenon.
@en
Particle size-dependent triggering of accelerated blood clearance phenomenon.
@nl
type
label
Particle size-dependent triggering of accelerated blood clearance phenomenon.
@en
Particle size-dependent triggering of accelerated blood clearance phenomenon.
@nl
prefLabel
Particle size-dependent triggering of accelerated blood clearance phenomenon.
@en
Particle size-dependent triggering of accelerated blood clearance phenomenon.
@nl
P2093
P1476
Particle size-dependent triggering of accelerated blood clearance phenomenon.
@en
P2093
Eriya Kenjo
Hiroshi Kiwada
Hiroyuki Koide
Kentaro Hatanaka
Masamichi Nishihara
Masayuki Yokoyama
Takayuki Ishii
Takeo Urakami
Tatsuhiro Ishida
P304
P356
10.1016/J.IJPHARM.2008.06.004
P407
P577
2008-06-07T00:00:00Z